Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547670 | 0.93 | MCL1 (0.48) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL612494 | 0.82 | MCL1 (0.60) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL3553694 | 0.82 | MCL1 (0.60) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL8081259 | 0.80 | MCL1 (0.58) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL28677273 | 0.80 | MCL1 (0.58) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL7353241 | 0.80 | MCL1 (0.58) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL17178416 | 0.80 | MCL1 (0.58) | MCL1MAPK1CA1CA2CA4 | |
| Ethane SCHEMBL4053553 | 0.78 | MCL1 (0.56) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL10458616 | 0.77 | MCL1 (0.55) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL16534456 | 0.77 | MCL1 (0.55) | MCL1MAPK1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0028445-B1 | ACRIDINONES, THEIR PREPARATION AND USE; INTERMEDIATES AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | claimed |
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Ivan Aleksandrovich Starikov | 2019-04-25 | — | — | US | disclosed |
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Ivan Aleksandrovich Starikov | 2019-04-25 | — | — | US | disclosed |
| EP-0028445-B1 | ACRIDINONES, THEIR PREPARATION AND USE; INTERMEDIATES AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| EP-0028445-A2 | Acridinones, their preparation and use; intermediates and their preparation | CIBA-GEIGY AG (CH) | 1981-05-13 | — | — | EP | disclosed |
| US-4258190-A | BY REACTING CYCLOHEXANONE AND AN OXALATE ESTER TO FORM A CYCLOHEXANONECARBOXYLATE INTERMEDIATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
| US-4256639-A | Process for the synthesis of isatin derivatives | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO (IT) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | OGDH, GOT1, OAT | MCL1 4772/4885MAPK1 1544/4885CA1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.